ANI Pharmaceuticals | ANIP - Selling And Administration Expenses


ANI Pharmaceuticals reported $73.66M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Heron Therapeutics USD 23.74M 605K Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Perrigo USD 267.3M 11.4M Mar/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026